Myonex to Acquire Creapharm’s Clinical & Commercial Packaging and Bioservices Business
15.3.2024 09:10:00 CET | Business Wire | Press release
Myonex, a leading global clinical trial supply company, has reached an agreement with the owners of Creapharm Group to acquire the Creapharm Clinical Packaging & Distribution and Commercial Packaging business and bioservices, headquartered in Reims, France with additional locations in Bordeaux and Bailly-Romainvilliers, France, and Marietta, Georgia, USA.
The completion of this transaction is subject to regulatory approvals.
This strategic acquisition will bring complementary strengths to the marketplace. Myonex is the market leader in drug sourcing and clinical trial prescription services with growing franchises in clinical packaging, labeling and distribution, and ancillary equipment and supply. Creapharm will bring scale and deep expertise in clinical packaging and distribution alongside existing franchises in commercial packaging and advanced therapy medicinal products (ATMPs) supply chain management.
“By combining, we will fill a gap in the market with broad and deep expertise, integrated services, and extraordinary client focus,” said James Lovett, CEO of Myonex. “Myonex looks forward to combining with our Creapharm colleagues to meet the needs of our clients with agility and speed.”
“Growing with Myonex is an obvious step for Creapharm to move forward, contributing our expertise and wide range of packaging solutions to their operations while we will expand the range of services we offer in support of always more effective, efficient, patient-centric clinical trials,” said Eric Placet, Creapharm’s CEO and Founder. “Creapharm is pleased to evolve the overall mission of Myonex through our complementary strengths and to provide scale and flexibility in meeting our clients’ needs.”
“We have complementary strengths and cultural alignment that make this an exciting solution for the industry, our colleagues and clients,” said Michael Cohen, Myonex’s Co-Owner, and Executive Chairman. “We share traditions of entrepreneurship and engagement with team members, as well as a commitment to social and environmental responsibility to ensure the success of our clients, clinical trial sites and patients.”
Conditional upon the successful completion of the transaction, Mike Cohen will continue as Executive Chairman and James Lovett as CEO of the combined company. Eric Placet will reinvest into Myonex as well as join Myonex’s Board of Directors further solidifying the relationship. Creapharm’s Carla Da Costa will join the combined management teams and Edouard Placet will also have a strategic and leadership role in the combined company.
About Myonex
Myonex is a leading global clinical trial supply company offering tailored solutions in drug sourcing, packaging & labeling, equipment & supplies, and market leading CTRx solution for each trial’s specific requirements and complexities. With our locations in the US, EU, and UK we partner with pharmaceutical and biotechnology companies, contract research organizations (CROs), and other clinical trial service providers seeking a flexible, comprehensive solution for their trial supply needs. Learn more at www.myonex.com.
About Creapharm
With decades of experience in global clinical trial supply management, Creapharm supports Pharma and Biotech key players with customized solutions. Creapharm has a strong expertise in cold-chain management and recently developed ultra-cold solutions to handle biologicals and ATMP supply chain management. For marketed health products, Creapharm offers expert commercial packaging services to pharmaceutical and food supplement industries. Learn more at www.creapharm-pharma.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240315996717/en/
Contact information
Maryanne Walsh
+1 267-307-0876
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
H.I.G. Capital Announces the Sale of DGS S.p.A.11.6.2024 12:00:00 CEST | Press release
H.I.G. Capital (“H.I.G.”), a leading global alternative investment firm with $62 billion of capital under management, is pleased to announce that an affiliate has signed a definitive agreement to sell its portfolio company, DGS S.p.A. (“DGS” or the “Group”), a leading firm in the Italian Information Technology market, to DGS Co-Founders and management team in partnership with ICG, a global alternative asset manager. Since its inception in 1997, DGShas supported blue-chip customers in the design, integration, and maintenance of complex IT systems, with a specialization in digital transformation and cybersecurity services. The Group currently has over 1,900 employees, revenues of approximately €300 million, and maintains a group of highly loyal clientele. During H.I.G.’s ownership, DGS has tripled in size and consolidated its position as a leading Italian firm in cybersecurity services and digital transformation. DGS offers its clients sophisticated and proprietary digital transformation
Evertas Names Nick Selby Head of European Underwriting11.6.2024 12:00:00 CEST | Press release
Evertas, the world’s first crypto insurance company, has named Nick Selby as its new Head of European Underwriting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611141887/en/ Nick Selby, Executive Vice President and Head of European Underwriting at Evertas (Photo: Business Wire) Selby, an accomplished information and physical security professional, brings two decades of expertise in public and private sector information security, physical security, and complex incident handling, as well as seven years of experience leading teams securing billions of dollars in cryptoassets. Previously, his roles included VP of the Software Assurance Practice at Trail of Bits, Chief Security Officer at Paxos Trust Company, and Director of Cyber Intelligence and Investigations at the NYPD Intelligence Bureau. “Nick is an extremely valuable addition to our European team,” said Evertas CEO and Co-Founder J. Gdanski. “His public and private
Owlet utvider globalt fotavtrykk med lanseringen av medisinsk-sertifisert Dream Sock™ i Storbritannia og over hele Europa11.6.2024 11:00:00 CEST | Pressemelding
Owlet, Inc. («Owlet» or the «Company») (NYSE:OWLT), pioneren innen smart spedbarnsovervåking, kunngjør i dag den britiske og europeiske lanseringen av Dream Sock. Dette er en smart babymonitor med levende helseavlesninger og varsler for friske spedbarn mellom 0-18 måneder og 2,5-13,6 kg. Dette innovative medisinske utstyret gir foreldre helse og viktig informasjon i sanntid, noe som gir uovertruffen trygghet. Denne pressemeldingen inneholder multimedia. Se hele pressemeldingen her: https://www.businesswire.com/news/home/20240611820341/no/ (Photo: Business Wire) «Vi er svært stolte over å lansere Dream Sock til omsorgspersoner over hele Storbritannia og Europa og gi millioner av foreldre mer trygghet mens babyen sover,» sa Kurt Workman, Owlets administrerende direktør og medgründer. «Dream Sock er nå et globalt produkt som er anerkjent som medisinsk nøyaktig og trygt, etter å ha gjennomgått regulatoriske autorisasjoner og sertifiseringer innenfor flere geografier. I dag er misjonen vår
V-Nova Surpasses 1000 Patent Milestone in Media Technology Innovation11.6.2024 10:00:00 CEST | Press release
V-Nova, a leading provider of data compression solutions, video compression technology, XR technology, AI acceleration and parallel processing for a multitude of industries including media and entertainment, today announced its milestone achievement of 1000 active technology patents. This accomplishment underscores V-Nova’s dedication to research and development and its commitment to protecting its intellectual property globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240611724561/en/ V-Nova’s patent portfolio spans more than 50 different jurisdictions. Including over 400 patents in Europe, over 200 in the Americas, over 100 in the United States specifically, and over 200 in Asia. V-Nova forged new directions in data processing to enhance digital experiences, maximize efficiency, reduce costs, and increase sustainability. The company leads the way with key international data compression standards for the video indust
Alipay+ Reveals Top Scorer Trophy Design for UEFA EURO 2024™11.6.2024 09:24:00 CEST | Press release
Alipay+, a suite of cross-border mobile payment and digitalization technology solutions operated by Ant International and an Official Partner of UEFA EURO 2024™, today revealed the trophy that will be awarded to the most prolific marksman at the UEFA EURO 2024™ finale on July 14 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240610328619/en/ The UEFA Top Scorer Trophy presented by Alipay+ is unveiled for UEFA EURO 2024™ (Photo: Business Wire) Sculpted in the shape of the Chinese character “支” (pronounced zhi, and meaning payment as well as support), the trophy reflects Alipay+’s dedication to supporting consumers to enjoy seamless payment and a broad choice of deals using their preferred payment methods while traveling abroad. The character also resembles the fleeting moment of a barefooted striker poised to shoot, evoking the original beauty and power of football – a game that united people across the wo